SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Bogdanoff who wrote (980)11/23/1997 3:24:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear David:

I agree with you that the move is for the best interests of share-holders. After all, the management members are the biggest share-holders (of course, JNJ may be a bigger share-holder, but not as individuals). However, the short term sell-off is also justified as most of the fund managers are not holding AMLN for long terms. They have to report to their clients every quarter if not every month. By the time the next trial III results come out next year, they may very well be working for somebody else already. The only thing we can do is to take advantage of their irrational moves.

Good luck to you.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News